Brief: Vertex Announces European Commission Approval Of ALYFTREK, A New Once-Daily CFTR Modulator For The Treatment Of Cystic Fibrosis
01/07/2025 12:35
July 1 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: VERTEX ANNOUNCES EUROPEAN COMMISSION APPROVAL OF ALYFTREK®, A NEW ONCE-DAILY CFTR MODULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS VERTEX PHARMACEUTICALS INC - ALYFTREK APPROVED FOR CF PATIENTS 6 YEARS AND OLDER IN EU VERTEX PHARMACEUTICALS INC - ALYFTREK TO BE AVAILABLE IN IRELAND, DENMARK, AND GERMANY Source text: ID:nBw4DS3z4a Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals Incorporated
See all newsBrief: Vertex Appoints Daniel Brennan To Its Board Of Directors
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Vertex rises after kidney disease drug shows promise in mid-stage study
Brief: Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria